MarketResearchNest.com adds “Global Graft Vs Host Disease (GVHD) Treatment Market 2017-2021” new report to its research database. The report spread across in 78 pages with tables and figures in it.
The research analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021. Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient’s adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor’s organ/cell are used for transplantation compared with autologous transplant, a transplant where individual’s cells have been used for transplant.
The publisher recognizes the following companies as the key players in the global graft vs host disease (GVHD) treatment market: Bristol-Myers Squibb, Novartis, Pfizer, and F. Hoffmann-La Roche.
Other Prominent Vendors in the market are: bbott, AbbVie, Allergan, Anterogen, Astellas Pharma, Athersys, Baxter, Caladrius, Cellular Biomedicine Group, Cipla, Eisai, Eli Lilly, GlaxoSmithKline, Glenmark, Helsinn Healthcare, Heron Therapeutics, Incyte Corporation, IPCA Laboratories, Kadmon Holdings, Lupin, Osiris Therapeutics, RedHill, Sanofi, Shire, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and ViaCyte.
One trend in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of GVHD treatment market as the market is completely based on off-label usage. These inorganic growth strategies include global merger and acquisition, partnerships and regional acquisition.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=253264 . (This is premium report, Single User License – USD 3500 and Multi User License – USD 4000)
According to the report, one driver in the market is increased prevalence of cancer. Globally, cancer is one of the life-threating diseases. As per National Institutes of Health (NIH), it is the second largest cause of death globally. As per National Cancer Institute, in the US alone, 1,685,210 new cancer cases and 595,690 cancer deaths were expected during 2016. The prevalence of this disease is growing at high rates and is expected to grow at higher rates in future too. Bone marrow transplant is widely preferred in various types of cancers.
Further, the report states that one challenge in the market is off-label use of drugs. GVHD is one of the clinical disorders arising due to tissue and organ transplantation. It is more commonly observed in allogeneic transplants where the tissue or organ from another donor is transplanted into an individual. There is no specific drug indicated for GVHD, and thus the current management of GVHD is based on the off-label use of various drug therapies. This off-label use of drugs is one of the biggest challenges in the global GVHD treatment market till date.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Inquire before buying at https://www.marketresearchnest.com/enquirybuy.php?reportid=253264 . (This is premium report, Single User License – USD 3500 and Multi User License – USD 4000)
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain